U.S. secures nearly all stocks of COVID-19 drug remdesivir
- 4 years ago
美, 렘데시비르 3개월 치 물량 싹쓸이...EU는 확보 위한 협상 중
The U.S. has reportedly bought nearly all the global supply of the COVID-19 drug remdesivir for the next three months.
CNN reported that the U.S. has secured 92 percent of the drugmaker's total production for July to September.
That's enough for 500-thousand treatment courses.
The EU is in talks to reserve doses for EU member states and is negotiating over the drug maker's production capacity.
Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials.
It's also the only drug that has an emergency use authorization from the U.S. Food and Drug Administration to treat the virus.
The U.S. has reportedly bought nearly all the global supply of the COVID-19 drug remdesivir for the next three months.
CNN reported that the U.S. has secured 92 percent of the drugmaker's total production for July to September.
That's enough for 500-thousand treatment courses.
The EU is in talks to reserve doses for EU member states and is negotiating over the drug maker's production capacity.
Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials.
It's also the only drug that has an emergency use authorization from the U.S. Food and Drug Administration to treat the virus.